- Atomo Diagnostics (AT1) has entered an agreement with PinkTech Design Private (DIVOC) to launch its COVID-19 antibody test in India
- This agreement will see DIVOC distribute the AtomoRapid COVID-19 on a non-exclusive basis to government and corporate entities as well as India’s home-visit network
- Once DIVOC has obtained product registration approval for professional use, which estimated for Q2 FY21, the Atomo will provide 77,000 antibody test kits
- Atomo will receive a fixed transfer price per unit as well as a percentage of revenue received on final product sales
- The AtomoRapid COVID-19 test is a single-use, handled, TGA approved device that gives an accurate result in as little as 15 minutes
- Atomo is up 7.14 per cent on the market and shares are trading for 37.5 cents each
